Gliomas represent the most commonly occurring tumors in the central nervous system and account for approximately 80% of all malignant primary brain tumors. With a high malignancy and recurrence risk, the prognosis of high-grade gliomas is poor, with a mean survival time of 12–18 months. While contrast-enhanced MRI serves as the standard diagnostic imaging modality for gliomas, it faces limitations in the evaluation of recurrent gliomas, failing to distinguish between treatment-related changes and tumor progression, and offers no direct therapeutic options. Recent advances in imaging modalities have attempted to address some of these limitations, including positron emission tomography (PET), which has demonstrated success in delineating tumor margins and guiding the treatment of recurrent gliomas. Additionally, with the advent of theranostics in nuclear medicine, PET tracers, when combined with therapeutic agents, have also evolved beyond a purely diagnostic modality, serving both diagnostic and therapeutic roles. This review will discuss the growing involvement of theranostics in diagnosing and treating recurrent gliomas and address the associated impact on quality of life and functional recovery.
Background: Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytic neoplasm with variable clinical behavior. To better characterize survival outcomes and prognostic factors in patients with malignant PXA tumors, we performed a population-based analysis using data from the SEER program. Methods: We queried the SEER database using ICD-O-3 histology code 9424/3 to identify patients diagnosed with PXA between 2000 and 2022. Univariate and multivariable Cox regression were performed on demographic, tumor, and treatment variables to identify independent prognostic factors, with Kaplan–Meier Curves estimating survival for these same variables. To predict patient-specific 5- and 10-year survival probabilities, we built a web-based nomogram. Results: Overall survival rates of our 597 PXA patients were 92.2%, 86.7%, 81.5%, 74.6%, and 68.3% at 1-, 2-, 3-, 5-, and 10-years, respectively. In multivariable analysis, age ≥50 years was independently associated with significantly worse OS (p < 0.001). Larger tumor size (3.0–6.0 cm or >6 cm) also predicted poorer outcomes compared to smaller tumor size (<3.0 cm) (p < 0.01). When compared to patients who received gross total resection alone (GTR), patients who received GTR with chemotherapy and radiation, GTR with radiation, subtotal resection (STR) with chemotherapy and radiation, and STR with radiation all had worse OS (p < 0.01). Interestingly, patients who received STR alone had no statistically significant difference in OS compared to patients who received GTR alone (p > 0.05). Conclusions: We conducted the largest retrospective cohort study and provide the first nomogram-based app developed for PXA patients as a means of analyzing survival. Our aim for this app is to guide clinicians in more meaningful discussions with their patients and to provide an evidence-based tool that is easily deployable in the clinic.